Apr 19 |
PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans
|
Mar 27 |
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
|
Mar 18 |
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
|
Mar 1 |
PMV Pharmaceuticals reports FY results
|
Mar 1 |
PMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial Results
|
Feb 29 |
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
|
Feb 26 |
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
|
Jan 18 |
PMV to focus on lead drug, slashes workforce by 30%
|
Jan 18 |
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
|
Jan 5 |
PMV Pharmaceuticals names Michael Carulli as CFO
|